Breaking News, Financial News

Financial Report: Amgen

U.S. product sales were flat at $2.9 billion in the quarter and included a $65 million unfavorable impact due to U.S. health care reform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 4Q Revenues: $3.8 billion (+1%) 4Q Earnings: $1.0 billion (+10%) FY Revenues: $15.1 billion (+3%) FY Earnings: $4.6 billion (flat) Comments: U.S. product sales were flat at $2.9 billion in the quarter and included a $65 million unfavorable impact due to U.S. health care reform. International product sales were up 3% to $891 million. Total product sales included a $26 million negative impact of foreign exchange. For the year, U.S. product sales increased 1% to $11.3 billion a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters